Resources and needs of research ethics committees in Africa: Preparations for HIV vaccine trials

IRB Ethics and Human Research

Volumn 28, Issue 2, 2006, Pages 1-9

  Milford, Cecilia ^a   Wassenaar, Douglas ^a   Slack, Catherine ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AFRICA; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; EMPIRICAL APPROACH; ETHICS; FINANCIAL MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PROFESSIONAL STANDARD;

BIOMEDICAL AND BEHAVIORAL RESEARCH; EMPIRICAL APPROACH;

AFRICA; AIDS VACCINES; CLINICAL TRIALS; COMMITTEE MEMBERSHIP; ETHICAL REVIEW; ETHICS COMMITTEES, RESEARCH; FINANCIAL SUPPORT; GUIDELINES; HIV INFECTIONS; HUMANS;

EID: 33645463991     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Kilama WL. Equipping Africa's Researchers for Global Collaboration. 2003. http://www.scidev.net/dossiers/index.cfm?fuse-action= dossierreaditem&dossier=5&type=3.
2. London L. Ethical oversight of public health research: Can rules and IRBs make a difference in developing countries? American Journal of Public Health 2002;92:1079-1084.
3. See ref. 1, Kilama 2003.
4. Kasper CK. Conduct of clinical trials in developing countries. Haemophilia 2002;8:166-169.
5. Rugemalila JB. Health research ethics for African countries. Acta Tropica 2001;78:S99-S103.
6. See ref. 2, London 2002;
7. see ref. 4, Kasper 2002.
8. Ofori-Anyinam O. Composition and responsibilities of ethics committees and investigators. Acta Tropica 2001;78:45-48.
9. Loff B, Hofman K, Muthuswamy V. Issues in Medical Ethics. The Global Forum for Bioethics in Research: Report of a Meeting, April-June 2001. http://www.fic.nih. gov/programs/bioethicsreport.html.
10. Loff B. Africans discuss ethics of biomedical research. Lancet 2002;359:956.
11. Benatar SR. Reflections and recommendations on research ethics in developing countries. Social Science and Medicine 2002;54:1131-1141.
12. Nuffield Council on Bioethics. The Ethics of Research Related to Healthcare in Developing Countries. London, UK: Nuffield, 2001.
13. See ref. 7, Ofon-Anyinam 2001;
14. see ref. 11, Nuffield Council 2002.
15. See ref. 11, Nuffield Council 2002.
16. National Council on Ethics in Human Research. Report on Site Visits. October 1998 to December 2001 (Canadian Report), 2002;
17. Emanuel EJ, Wood A, Fleischman A, et al. Oversight of human participants research: Identifying problems to evaluate reform proposals. Annals of Internal Medicine 2004;141:282-291.
18. UNAIDS. Ethical Considerations in HIV Preventive Vaccine Research. Geneva, Switzerland: UNAIDS, 2000.
19. Guenter D, Esparza J, Macklin R. Ethical considerations in international HIV vaccine trials: Summary of a consultative process conducted by the joint United Nations programme on HIV/AIDS (UNAIDS). Journal of Medical Ethics 2000;26:37-43.
20. Lindegger G, Richter LM. HIV vaccine trials: Critical issues in informed consent. South African Journal of Science 2000;96:313-317.
21. Bloom BR. The highest attainable standard: Ethical issues in AIDS vaccines. Science 2000;279:188-2005;
22. Slack C, Stobie M, Milford C, et al. Provision of HIV treatment in HIV preventive vaccine trials: A view from South Africa. Social Science and Medicine 2005;60:1197-1208;
23. Tucker T, Slack C. Not if but how? Caring for HIV-1 vaccine trial participants in South Africa. Lancet 2003;362:995.
24. See ref. 10, Benatar 2002.
25. Effa P, Massougbodgi A, Ntoumi F, et al. Ethics Committees in West and Central Africa: Concrete Premises for a Clinical Research Partnership (Report No. 37); 2003. (Translated from French.)
26. See ref. 1, Kilama 2003.
27. Sumathipala A, Siribaddana S, Patel V. Under-representation of developing countries in the research literature: Ethical issues arising from a survey of five leading medical journals. BMC Medical Ethics 2004;5:5-10.
28. Kass N, Hyder AA. Attitudes and experiences of U.S. and developing country investigators regarding U.S. human subjects regulations. Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries. Vol. II: Commissioned Papers, National Bioethics Advisory Commission, Bethesda, MD. 2001;B1-B189.
29. Kim O-J, Park O-J, Lee S-M, et al. Current status of the Institutional Review Boards in Korea: Constitution, operation and policy for protection of research participants. In Song SY, Koo YM, Macer DRJ, eds. Bioethics in Asia in the 21st Century. Eubios Ethics Institute, 2003, p. 17-27. http://www.biol. tsukuba.ac.jp/~macer/ABC4/abc4017.htm.
30. Kass N, Dawson L, Loyo-Berrios NI. Ethical oversight of research in developing countries. IRB: Ethics & Human Research 2003;25:1-10;
31. see ref. 24, Kim et al. 2003.
32. See ref. 24, Kim et al. 2003.
33. Hyder AA, Wali SA, Khan AN, Teoh NB, Kass NE, Dawson L. Ethical review of health research: A perspective from developing country researchers. Journal of Medical Ethics 2004;30:68-72.
34. See ref. 27, Hyder et al. 2004.
35. Mugerwa RD, Kaleebu P, Mugyeni P, et al. First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ 2002;324:226-229;
36. Weidle PJ, Mastro TD, Grant AD, et al. HIV/AIDS treatment and HIV vaccines for Africa 2002;359:2261-2267.
37. See ref. 29, Mugerwa et al. 2002.
38. Bhatt KM. Challenges faced in reviewing HIV vaccine trial protocols. Paper presented at the meeting of the African AIDS Vaccine Programme, June 16-18, 2003, Addis Ababa, Ethiopia.
39. Karashani JT. National regulatory procedures: Perspective from African countries. Paper presented at the meeting of the African AIDS Vaccine Programme, June 16-18, 2003, Addis Ababa, Ethiopia;
40. ref. 31, Bhatt 2003.
41. See ref. 32, Karashani 2003.
42. HIV Vaccine Initiative (HVI) (WHO/UNAIDS Collaboration). Country Profiles of HIV Vaccine Involvement (Pamphlet), 2002.
43. Thior I. Experience from Botswana. Paper presented at the meeting of the African AIDS Vaccine Programme, June 16-18, 2003, Addis Ababa, Ethiopia.
44. SAPA. SA vaccine trials approved: World-first trial of ARV-technology vaccine to take place in SA and US; 2003. http://www.witness.co.za/content/ 2003_06/16200. htm.
45. Contact details were placed on the following website: http://www.saavi.org.za/inventory.htm.
46. EFGCP. European Guidelines for Auditing Independent Ethics Committees. Belgium: EFGCP, 2002.
47. U.S. Department of Health and Human Services. Office for Human Research Protections (OHRP). Quality Assurance Self Assessment Tool 2002, http://ohrp.osophs .dhhs.gov/humansubjects/qip/qatooli.htm.
48. Fox RJ, Crask MR, Kim J. Mail survey response rate: A meta-analysis of selected techniques for inducing response. Public Opinion Quarterly 1988;52, 467-491;
49. see ref. 25, Kass et al. 2003.
50. See ref. 15, UNAIDS 2000.
51. World Medical Association (WMA). Declaration of Helsinki. Somerset West: 48th General Assembly, WMA, 1996.
52. Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland: CIOMS & WHO, 2002.
53. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: U.S. Government Printing Office, 1979.
54. See ref. 15, UNAIDS 2000.
55. See ref. 29, Mugerwa et al. 2002.
56. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how? Lancet 2000;355:2061-2066.
57. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-2711.
58. See ref. 15, UNAIDS 2000.
59. Beauchamp TL, Childress JF. Principles of Biomedical Ethics, 5th ed. Oxford, UK: Oxford University Press, 2001.
60. Allen M. Trial-related discrimination in HIV vaccine clinical trials. AIDS Research and Human Retroviruses 2001;17:667-668.
61. Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. Journal of Acquired Immune Deficiency Syndromes and Human Retroviruses 1995;9:30-35.
62. King N. Defining and describing benefit appropriately in clinical trials. Journal of Law, Medicine & Ethics 2000;28:334.
63. See ref. 27, Hyder et al. 2004;
64. see ref. 25, Kass et al. 2003.
65. Policy Forum. Fair benefits for research in developing countries. Science 2002;298:2133-2134.
66. Editorial. The trials of clinical trials. Lancet 2005;365:1111;
67. Jinktarkanon S, Nakapiew S, Tienudom N, et al. Unethical clinical trials in Thailand: A community response. Lancet 2005;365:1617-1618.
68. See ref. 32, Karashani 2003;
69. see ref. 24, Kim et al. 2003.
70. See ref. 25, Kass et al. 2003.
71. See ref. 14, National Council 2001;
72. see ref. 24, Kim et al. 2003.
73. See ref. 7, Ofori-Anyinam 2001.
74. See ref. 11, Nuffield 2002.
75. See ref. 48, Emanuel et al. 2000.